New York jury holds drug firm Teva liable in opioid crisis
Does Teva Pharmaceutical Deserve a Place in Your 2022 Portfolio?
Teva Generic Medicines Saved the United States $28.8 Billion in 2020, and a Total of $43.1 Billion Across Major Markets, According to Independent Analysis
Teva Pharmaceuticals found to be responsible for its role in the opioid epidemic in New York State | CNN
Teva Pharmaceuticals found liable in New York opioid trial - BBC News
Transitioning Teva revamps branding to emphasize brand-generic unity | Fierce Pharma
Teva pharmaceuticals Stock Photo - Alamy
Perrigo, Catalent get generic of Teva inhaler approved on 4th go-round | Fierce Pharma
Teva Announces Share Pricing Pending Actavis Generics Acquisition | Teva pharmaceuticals, Teva, Pharmaceutical industry
News of Note—Teva accused of shortcutting plant sale; Sun plant gets only one observation | Fierce Pharma
Teva Pharmaceuticals is found liable in the opioid crisis : NPR
Teva Pharmaceutical: Generic Market Access to Global Healthcare Industry | IntechOpen
FiercePharmaAsia—Teva's China JV? Lupin plants' roadblock, EOC's $32M series B | Fierce Pharma
Pharmaceutical Company Reaches Settlement With Oklahoma In Opioid Case : NPR
Teva Announces Launch of $4,000,000,000 Offering of Sustainability-linked Senior Notes | Business Wire
FDA rejects schizophrenia drug from Teva
Insilico collaborates with Teva on AI system | EurekAlert!
Teva Reports Fourth Quarter and Full Year 2020 Financial Results | Business Wire
Teva Zymic
Teva Unveils New Spring 2022 Collection
ADDING MULTIMEDIA Teva Announces U.S. Approval of AJOVYTM (fremanezumab-vfrm) Injection, the First and Only Anti-CGRP Treatment with Both Quarterly and Monthly Dosing for the Preventive Treatment of Migraine in Adults | Business
Direct Relief, the National Association of Free and Charitable Clinics and Teva Pharmaceuticals Partner to Advance Access to Behavioral Health Services | The National Association of Free & Charitable Clinics
Teva stock plummets 18% after rough quarter in US generic drug market
teva News and latest stories | The Jerusalem Post
Teva: Definitely Undervalued (NYSE:TEVA) | Seeking Alpha
Buy Teva Pharmaceuticals amid positive news, Bernstein says
